Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Proposals Elicit Cautious Response From Device Center Director

This article was originally published in The Gray Sheet

Executive Summary

CDRH would not welcome a user fee proposal that benefited one premarket review path while taking funds away from others, device center Director David Feigal, MD, asserted April 17

You may also be interested in...



Device Center Modular PMA Submissions Down In FY 2001

FDA received fewer PMA shells and modules in FY 2001 than in previous years, while the proportion of PMA modules found deficient compared to those found acceptable increased

FDA Aims For Greater Efficiency Under Modular PMA Revamp

FDA wants to limit the number of premarket components sponsors can submit under its modular PMA program in order to ensure efficient use of its device review resources.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
UsernamePublicRestriction

Register

MT016455

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel